Active Biotech's Prostate Cancer Project TASQ Featured in British
Journal of Cancer
(Thomson Reuters ONE) - Lund, Sweden, September 25, 2009- British Journal of Cancer (doi:10.1038/sj.bjc.6605322) releases an article covering Active Biotech's(NASDAQ OMX Nordic: ACTI) prostate cancer project TASQ, where TASQwas studied as a single agent in patients with castration-resistantprostate cancer.Two open-label phase I clinical trials in patients withcastration-resistant prostate cancer were conducted to evaluate thesafety and tolerability of TASQ, with additional pharmacokinetic andefficacy assessments.The results showed that long-term continuous oral administration ofTASQ seems to be safe, and the overall efficacy results indicate thatTASQ might delay disease progression.A total of 32 patients were enrolled; 21 patients were maintained for>=4 months. The median PSA progression-free time was 19 weeks. In 15patients, radiologic imaging with bone scan was done at screening andevery 2 months until the final visit. It is noteworthy that there wasno finding of bone scan progression at end of study in 80% of thepatients (median treatment time 34 weeks; range 15 - 54 weeks).TASQ is presently in development for the treatment of metastaticcastration-resistant prostate cancer. A phase II study, which hascompleted enrollment of over 200 patients, is currently ongoing. Theresults from this study are expected in late 2009/early 2010.Active Biotech AB (publ)Tomas LeandersonPresident & CEOFor further information, please contactTomas Leanderson, President & CEOTel: +46 46 19 20 95tomas.leanderson(at)activebiotech.comGöran Forsberg, VP IR & Business DevelopmentTel: +46 46 19 11 54goran.forsberg(at)activebiotech.comNotes to editorsAbout TASQThe development of TASQ is principally focused on the treatment ofprostate cancer. TASQ is an antiangiogenic compound, meaning that itcuts off the supply of nutrients to the tumor but it does not belongto the most frequently occurring group of tyrosine kinase inhibitors.Positive results for the concluded Phase I trial show that TASQ iswell-tolerated and has a favorable safety profile. In September 2008,the follow-up efficacy data from the Phase Ib trial of TASQ waspresented, which showed that patients treated with TASQ developed fewnew bone metastases and displayed a reduced rate of increase of thedisease marker PSA (Prostate-Specific Antigen). The project iscurrently in a clinical Phase II trial in progress in the US, Canadaand Sweden. The trial is a 2:1 random, placebo-controlled,double-blind study of 1mg/day TASQ, compared with placebo. The studyincludes symptom-free patients with metastasized, hormone-resistantprostate cancer. Information about the ongoing clinical trial isavailable at www.activebiotech.com and www.clinicaltrials.gov.About Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech is required under the Securities Markets Act to makethe information in this press release public. The information wassubmitted for publication at 08:30 am CET on September 25, 2009.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 25.09.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 6231
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 356 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's Prostate Cancer Project TASQ Featured in British
Journal of Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
